Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
C.ChoiM
April 2025 | Volume 24 | Issue 4 | 413 | Copyright April 2025 Published online March 7, 2025 doi:10.36849/JDD.8605 Sophia Daniel BS a,b , Stephanie Waggett BS a,c , Elliott Lyles BS a , Pelin Sagut MD a,d , Parisa Shamaei Zadeh MSPH b , Anthony Marcelletti BHS b , Carol Stegura ME c , Lara Wine Lee MD PhD d a College of Graduate Studies, Medical University of South Carolina, Charleston, SC b College of Medicine, University of Kentucky, Lexington, KY c College of Medicine, Medical University of South Carolina, Charleston, SC d Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC Abstract Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss
Both drugs changed how doctors and patients think about treating obesity
These localised reactions usually resolve within a few days and are considered a normal response to subcutaneous injection rather than an immune-mediated allergic reaction
If approved, copays can be as low as $25 per month
10.1128/JB.00647-09 J
US$ 25.58
US$ 21.48
US$ 28.02
US$ 22.24
